<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02939495</url>
  </required_header>
  <id_info>
    <org_study_id>NEU-16.12</org_study_id>
    <secondary_id>16-NEU-1</secondary_id>
    <nct_id>NCT02939495</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Dapoxetine/Sildenafil Combination Therapy</brief_title>
  <acronym>DAP-SPEED</acronym>
  <official_title>The Efficacy and Safety of Dapoxetine/Sildenafil Combination Therapy in the Treatment of Men With Premature Ejaculation and Erectile Dysfunction (DAP-SPEED Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neutec Ar-Ge San ve Tic A.Ş</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neutec Ar-Ge San ve Tic A.Ş</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Dapoxetine/Sildenafil
      30/50 mg film-coated tablet in the treatment of men with premature ejaculation and erectile
      dysfunction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During 4-weeks treatment period, patients will take one Dapoxetine/Sildenafil 30/50 mg film
      coated tablet 1-3 hours before sexual intercourse.

      Study drug should not be used more than 1 tablet every 24 hours during the treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The evaluation of change in Intra-vaginal Ejaculation Latency Time (IELT) compared to baseline.</measure>
    <time_frame>4-weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The evaluation of IIEF-15 (International Index of Erectile Function Questionnaire) score compared to baseline.</measure>
    <time_frame>4-weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The evaluation of premature ejaculation symptom scores compared to baseline.</measure>
    <time_frame>4-weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The evaluation of Premature Ejaculation response measured by Premature Ejaculation Profile (PEP)</measure>
    <time_frame>4-weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Rate of Premature Ejaculation Profile (PEP) response</measure>
    <time_frame>4-weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The evaluation of safety of study drug (Number of Participants with Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment)</measure>
    <time_frame>4-weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Premature Ejaculation</condition>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Study drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapoxetine/Sildenafil 30/50 mg film coated tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapoxetine/Sildenafil 30/50 mg film coated tablet</intervention_name>
    <description>1 tablet before sexual intercourse</description>
    <arm_group_label>Study drug</arm_group_label>
    <other_name>Dapoxil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-64 years old men,

          -  Participants must be heterosexual males and in a stable monogamous sexual relationship
             with a female partner for at least 6 months and will continue throughout the study,

          -  Clinical diagnosis of erectile dysfunction, IIEF score ≤21,

          -  Premature Ejaculation Diagnostic Tool (PEDT) score must be ≥11

          -  Patients with life-long PE and acquired PE according to the description of
             International Society for Sexual Medicine (ISSM) ,

          -  The patient and his partner must have sexual intercourse twice a week for the duration
             of the study,

          -  Commitment to comply with the study protocol,

          -  Patients who sign informed consent form (ICF).

        Exclusion Criteria:

          -  History of medical events such as surgical interventions or neurologic conditions
             (e.g., multiple sclerosis), trauma, or infections that are associated with the
             development of symptoms of premature ejaculation (PE) and considered a potential cause
             of PE,

          -  Having genital abnormalities, except penile curvature unless not prevent sexual
             intercourse,

          -  Developed ED or PE due to drug use or quit taking drugs,

          -  Any conditions that prevent sexual intercourse with partners

          -  History of epilepsy,

          -  Severe renal insufficiency,

          -  Liver disease,

          -  History of in last 6 months stroke, myocard infarction, cardiac insufficiency (New
             York Cardiovascular Associates (NYCA) phase II-IV), AV block or message disorder such
             as sick sinus syndrome, severe ischemic cardiac disease, syncope, unstable angına,
             life-threatening arrhythmia or hypotension,

          -  Non-Arteritic Anterior ischemic optic neuropathy,

          -  Patients who are not eligible to have sexual intercourse due to existing health
             problems,

          -  Autonomic neuropathy, retinitis pigmentosa, blood diseases, active peptic ulcer,
             abnormalities in ECG, severe systemic disease that cannot be controlled,

          -  Systolic/Diastolic blood pressure at rest &lt;90/50mmHg and 170/100mmHg&lt;

          -  History of allergy to Selective Serotonine Reuptake Inhibitor (SSRI) and
             phosphodiesterase inhibitor drugs,

          -  Continuing to use or quitted in last 3 months of Monoamine oxidase inhibitor (MAOI),
             Thioridazine, Serotonine Reuptake Inhibitor (SSRI), Selective-Norepinephrin Reuptake
             Inhibitor (SNRI), Serotonergic drug/herbal product, tricyclic antidepressant and
             atypical antipsychotic drugs,

          -  Use of nitrates, alfa blockers, vasodilators, ketoconazole, itraconazole, ritonavir,
             saquinavir, telithromycin, nefazodone, nelfinavir, atazanavir, cimetidine,
             erithromicin, clarithromycin, fluconazole, amprenavir, fosamprenavir, aprepitant,
             verapamil, diltiazem, any kind of vasodilator, antiplatelet, anticoagulant,
             dapoxetine, PDE5 inhibitor, alcohol and stimulant drug,

          -  Patients on a different therapy (behavioral therapy or other drugs that are applied
             locally) for PE treatment

          -  During the study, the possibility of taking medication which may affect the study
             drug's pharmacokinetic/pharmacodynamic properties

          -  Patients who are defining symptoms of prostatitis clinically

          -  Thyroid hormone disorders
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ege Can Şerefoğlu, Assoc Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Bağcılar Research and Training Hospital Urology Dep.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bagcilar Training and Research Hospital Urology Dep.</name>
      <address>
        <city>Istanbul</city>
        <zip>34100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2016</study_first_submitted>
  <study_first_submitted_qc>October 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2016</study_first_posted>
  <last_update_submitted>December 12, 2017</last_update_submitted>
  <last_update_submitted_qc>December 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Premature Ejaculation</keyword>
  <keyword>Erectile Dysfunction</keyword>
  <keyword>DAP-SPEED</keyword>
  <keyword>Dapoxetine</keyword>
  <keyword>Sildenafil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Erectile Dysfunction</mesh_term>
    <mesh_term>Premature Ejaculation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

